Abstract
Malignant pleural and peritoneal effusions are frequent complications in advanced lung cancer, typically signaling a poor prognosis. This case report describes a 58-year-old male with advanced ROS1-rearranged lung adenocarcinoma who presented with persistent, treatment-resistant effusions. Following the failure of standard chemotherapy, the patient received a combination of Crizotinib and Anlotinib. This dual-targeted approach led to the rapid resolution of effusions and sustained remission for over four years, suggesting a potent strategy for managing refractory malignant effusions in specific NSCLC subsets.
The Challenge of Malignant Effusions in Advanced NSCLC
Advanced non-small cell lung cancer (NSCLC) often involves the accumulation of excess fluid in the pleural and peritoneal cavities. These malignant effusions are indicators of advanced disease progression, often associated with a median survival of only 3 to 6 months. Patients suffer from significant respiratory distress and abdominal impairment, severely impacting their quality of life.
While Tyrosine Kinase Inhibitors (TKIs) have transformed treatment for patients with genetic drivers like ROS1 rearrangements (found in 1-2% of NSCLC cases), persistent effusions often remain refractory to standard systemic therapies. Conventional management frequently provides only transient relief.
Case Presentation and Therapeutic Strategy
A 58-year-old male patient was diagnosed with advanced lung adenocarcinoma. Initial genetic testing was negative, and the disease progressed through seven cycles of chemotherapy, characterized by worsening pleural and peritoneal effusions. Subsequent high-throughput sequencing identified a ROS1 rearrangement, prompting a novel combination regimen: Crizotinib (250 mg twice daily) to target the ROS1 fusion protein, and Anlotinib (10 mg once daily, 2-weeks-on/1-week-off) to target the VEGF, FGFR, and PDGFR pathways.
Clinical Response and Long-term Outcomes
The patient's response was both rapid and durable. Within one month of treatment initiation, clinical imaging confirmed a dramatic reduction in fluid accumulation.
As shown in the baseline imaging, the patient initially presented with significant fluid levels compromising organ function. Following the introduction of the Crizotinib-Anlotinib combination, follow-up scans demonstrated near-complete resolution of these effusions.
The patient achieved stable disease for over four years, far exceeding typical survival expectations. The treatment was well-tolerated, with Grade 2 hypertension being the only notable side effect, managed successfully with standard medication.
Mechanistic Insights: A Dual-Targeted Approach
The success of this "double-hit" strategy likely arises from synergistic molecular mechanisms. Crizotinib directly inhibits the ROS1 signaling pathway driving tumor proliferation, while Anlotinib targets the Vascular Endothelial Growth Factor (VEGF) pathway. VEGF is a primary driver of capillary permeability; by inhibiting it, Anlotinib directly addresses the physiological cause of fluid leakage. Furthermore, anti-angiogenic agents may help overcome potential resistance to Crizotinib by altering the tumor microenvironment.
Conclusion
This case highlights the potential of combining targeted TKIs with anti-angiogenic agents to manage complex, refractory symptoms in advanced NSCLC. While further validation through multicenter clinical trials is necessary, this regimen represents a viable strategy to improve both survival and quality of life for patients with ROS1-rearranged lung adenocarcinoma and persistent malignant effusions.
Summary updated